Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis IM136003
The purpose of this study is to test the effectiveness of an investigation drug at slowing the decline of lung function in individuals with pulmonary fibrosis by comparing two different doses of the drug vs placebo.
You must be between the ages of 40 and 80 and have had symptomatic pulmonary fibrosis for at least 12 months before enrollment into the study.
40 - 90
Healthy Volunteers Needed
Duration of Participation
Nathan Kessler: 503-494-9570, Kesslena@ohsu.edu
Bristol Myers Squibb Company